CD8A and neoplasm: Nevertheless, patients with high PD-L1 and TMB may not benefit from ICIs and ACT due to the lack of tumour-specific effector T cells, considering the vast majority of tumour-infiltrating CD8+ T cells were bystanders without response to tumour-specific neoantigens [35].